Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 484

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 484
---
quired in process research and development (“IPR&D”). On January 26, 2023, TuHURA acquired certain assets of TuHURA Biopharma, for $1.2 million in cash and 4.1 million shares of Legacy TuHURA common stock. The common shares issued to TuHURA Biopharma had an estimated fair market value of $15.0 million. TuHURA performed the “screen test” and determined that substantially all of the fair value of the gross assets acquired in the TuHURA Biopharma acquisition was concentrated in a single identifiable asset or group of similar identifiable assets. As such, the TuHURA Biopharma acquisition has been accounted for as an asset acquisition. As the underlying asset is in-process research and development, we immediately expensed the entire $16.2 million purchase price for the year ended December 31, 2023, in accordance with FASB ASC Topic 730. 309

General and Administrative Expenses.General and administrative expenses were
$4.3 million and $4.1 million for the years ended December 31, 2024, and 2023, respectively. The increase of $0.2 million was primarily due to increases in non-cash stock compensation expense and costs associated with being a public company
incurred in 2024 offset by decrease in legal fees associated with the subsequently abandoned proposed merger with CohBar, Inc. which were incurred in 2023.

Employee Retention Tax Credit.The IRS provided a refundable tax credit for businesses that had employees that were affected during the
COVID-19 pandemic. In October 2022, TuHURA applied for a credit under this program and in May 2023, TuHURA received notice that the credit would be $0.3 million of which $0.1 million was received in 2024.

Grant Income.Grant income was $0.1 million and less than $0.1 million for the years ended December 31, 2024 and 2023, respectively. In
April 2021, TuHURA received approval from the Department of Health and Human Services for a $0.4 million grant to study cervical cancer and received reimbursements for related expenses associated with the grant. TuHURA received the final payment
under this grant in May 2023. Additionally, in October 2024, TuHURA assumed the Kintara Health and Human Services grant on REM-001 and received reimbursements for related expenses associated with